本文发表在 rolia.net 枫下论坛Novartis:
NOVARTIS (NVS - $50.31) TO ACQUIRE UP TO 77% OF ALCON, THE
WORLD'S LARGEST EYE CARE COMPANY; COMPANY TO TEMPORARILY SUSPEND SHARE
REPURCHASES IN LIGHT OF INCREASING DEBT
Early this morning, Novartis announced that is has acquired 25% of consumer
eye care business Alcon from Nestle with potential to acquire 52% more at a
later date. The deal, valued in total at $39 billion, further diversifies
Novartis at a time when patent protection and FDA approval of pipeline drugs
continue to plague pharmaceutical companies. Additionally, Novartis announced
they are suspending their share repurchase program temporarily as they focus
on paying down the $5.5 billion in debt they have raised for the deal.
--------------------------------------------------
My company will issue another client-approved research report this week discussing the health care industry:
REFILL YOUR PORTFOLIO WITH GENERIC DRUGS"
This new report addresses the growth opportunity in generic drugs and how
clients can invest in this opportunity.
We believe generic drug growth will be driven by:
- an estimated $65 billion in major brand-name drugs expected to go generic
over the next five years
- an aging population increasing its usage of drugs, including generics
- ongoing efforts by payers to control drug costs, thereby encouraging the
use of low-cost generics更多精彩文章及讨论，请光临枫下论坛 rolia.net
NOVARTIS (NVS - $50.31) TO ACQUIRE UP TO 77% OF ALCON, THE
WORLD'S LARGEST EYE CARE COMPANY; COMPANY TO TEMPORARILY SUSPEND SHARE
REPURCHASES IN LIGHT OF INCREASING DEBT
Early this morning, Novartis announced that is has acquired 25% of consumer
eye care business Alcon from Nestle with potential to acquire 52% more at a
later date. The deal, valued in total at $39 billion, further diversifies
Novartis at a time when patent protection and FDA approval of pipeline drugs
continue to plague pharmaceutical companies. Additionally, Novartis announced
they are suspending their share repurchase program temporarily as they focus
on paying down the $5.5 billion in debt they have raised for the deal.
--------------------------------------------------
My company will issue another client-approved research report this week discussing the health care industry:
REFILL YOUR PORTFOLIO WITH GENERIC DRUGS"
This new report addresses the growth opportunity in generic drugs and how
clients can invest in this opportunity.
We believe generic drug growth will be driven by:
- an estimated $65 billion in major brand-name drugs expected to go generic
over the next five years
- an aging population increasing its usage of drugs, including generics
- ongoing efforts by payers to control drug costs, thereby encouraging the
use of low-cost generics更多精彩文章及讨论，请光临枫下论坛 rolia.net